Biotech Values

[upndown1313]

from Briefing.com today: Piper Jaffray says they have learned that the Viropharm (VPHM 12.14) Phase II HCV-796 trial has opened for enrollment and the first patient was enrolled during the first week of October. Given the timeline proposed by Wyeth, the firm estimates that enrollment should be completed in November and preliminary data from the one-month interim analysis could be available in 1Q07. They
remain encouraged by the initial data for HCV-796 and await further data to elucidate its potential market opportunity..

looks like head-to-head battle here with R1626...IDIX still hampered by dose limiting toxicity